Entrada Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Entrada Therapeutics, Inc. on June 2, 2022. The meeting was conducted in a virtual-only format via live webcast. As of the record date (April 5, 2022), there were 31,364,089 shares of Common Stock outstanding entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on two proposals. A quorum was established with 18,309,559 shares present or represented by proxy.
- Proposal No. 1 (Election of Directors): Three Class I director nominees were elected to serve until the 2025 annual meeting.
- Proposal No. 2 (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Director Election Results: Dipal Doshi received 16,755,890 "For" votes; Kush M. Parmar received 13,773,852 "For" votes; Mary Thistle received 16,751,000 "For" votes.
- Auditor Ratification: Ernst & Young LLP received 18,307,689 "For" votes with zero "Against" votes.
- Broker Non-Votes: There were 222,902 broker non-votes recorded for the director election proposals.
- Meeting Attendance: Approximately 58% of outstanding shares were present or represented at the meeting.